About This Source - Bloomberg QuickTake: Now
Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City.
It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.
Recent from Bloomberg QuickTake: Now:
Bloomberg Quicktake: Now published this video item, entitled “AstraZeneca-Oxford Vaccine Found Effective in Preventing Covid” – below is their description.
A Covid-19 vaccine developed by the University of Oxford and AstraZeneca Plc prevented a majority of people from getting the disease in a large trial, another promising development in the quest to end the pandemic, and the rollout could begin next month. The vaccine stopped an average of 70% of participants from falling ill, an early analysis of the data show. The effectiveness rose to 90% for one of two regimens, using half a dose followed by a full one later, close to the high bar set by Pfizer Inc. and Moderna Inc. Astra and Oxford officials said they’re preparing to submit the findings to regulators and don’t expect the different outcomes in the study to affect the process. The U.S. could potentially take longer to sign off because a clinical trial in that country will need more time before it delivers results. “Our goal was to make sure we can have a vaccine that is accessible everywhere,” Andrew Pollard, who is leading the Astra-Oxford trials, said Monday at a press briefing. “I think we have actually managed to do that.” The results, based on trials in the U.K. and Brazil, were reviewed after 131 participants contracted Covid-19. The full two doses showed an efficacy of 62%. Among those who received the vaccine, there were no severe cases and no participants were hospitalized. The group is planning to submit the data for peer review in the next 24 hours. Astra shares dropped as much as 3.2% in London, losing ground after SVB Leerink analyst Geoffrey Porges said the vaccine would “never be licensed” in the U.S. because of questions around the data. Highlighting the 90% efficacy in a subset of trial participants was an effort to “embellish” the results, he said. “The suggestion by the inventors that the small sample given the lower priming dose was evidence of superior efficacy only brings discredit to the program,” Porges said in a report. Astra didn’t immediately comment on the note. The stock is still up about 30% since mid-March, but Moderna and Pfizer shares surged when they reported their results. The larger U.S. Astra trial, which could be key for approval there, has injected about 10,500 people with both doses. Mene Pangalos, Astra’s head of biopharma research, told reporters the team is planning to talk to the U.S. Food and Drug Administration immediately and hopes to have another arm administering the half dose-full dose regimen starting within weeks. “That scenario is possible,” that other regulators could move before the U.S., he said. “We need to share the data with the FDA, which we will do very quickly, and then we will work out what the most appropriate steps are.” Despite the apparently lower efficacy than shots from Pfizer and Moderna, which each prevented about 95% of cases, the British vaccine has some advantages. Their shot can be kept at refrigerator temperatures, while those from Pfizer and Moderna, based on novel messenger RNA technology, require freezing for longer-term storage and transport. That would make Astra’s easier to deploy globally, particularly in lower- and middle-income countries. It also comes at a lower cost. The Astra-Oxford team cautioned against comparing the efficacy levels of the vaccines too closely at this stage. Pam Cheng, who runs Astra’s global operations and is overseeing the manufacturing of the vaccine, said the half dose-full dose regimen shouldn’t affect global production or supplies of the shot, other than to potentially increase the number of doses available. AstraZeneca expects to have more than 300 million doses ready to ship globally by the end of the first quarter of next year, with about 100 to 200 million doses being produced monthly. For the U.K., the company expects to have up to 4 million doses ready by year-end, and 40 million by the end of the first quarter. The differing results of the two regimens may leave questions about the best way to give the AstraZeneca shot. Analysts at Barclays Plc had put consensus expectations for what would be deemed a success from AstraZeneca at 70% to 90%, following conversations with investors in Europe and the U.S. Subscribe to our YouTube channel: https://bit.ly/2TwO8Gm Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world. To watch complete coverage on Bloomberg Quicktake 24/7, visit http://www.bloomberg.com/qt/live, or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app. Connect with us on… YouTube: https://www.youtube.com/user/Bloomberg Breaking News on YouTube: https://www.youtube.com/c/BloombergQuickTakeNews Twitter: https://twitter.com/quicktake Facebook: https://www.facebook.com/quicktake Instagram: https://www.instagram.com/quicktakeBloomberg Quicktake: Now YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.
In This Story: AstraZeneca
AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.
3 Recent Items: AstraZeneca
In This Story: Brazil
Its capital is Brasília, and its most populous city is São Paulo. The federation is composed of the union of the 26 states and the Federal District. It is the largest country to have Portuguese as an official language and the only one in the Americas, as well as the most populous Roman Catholic-majority country.
Its Amazon basin includes a vast tropical forest, home to diverse wildlife, a variety of ecological systems, and extensive natural resources spanning numerous protected habitats. Brazil is classified as an upper-middle income economy by the World Bank and a newly industrialized country.
2 Recent Items: Brazil
In This Story: COVID-19
Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.
Symptoms of coronavirus
The main symptoms of coronavirus are:
- a persistent new cough (non productive, dry)
- a high temperature (e.g. head feels warm to the touch)
- shortness of breath (if this is abnormal for the individual, or increased)
Latest News about Covid-19
Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.
5 Recent Items: COVID-19
In This Story: London
4 Recent Items: London
In This Story: Moderna
Moderna is an American biotechnology company based in Cambridge, Massachusetts that focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.
CEO: Stéphane Bancel (2011–)
Stock ticker: (NASDAQ:MRNA)
5 Recent Items: Moderna
In This Story: Pfizer
Pfizer Inc. (NYSE: PFE) is an American multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.